Matt Zuga - Jul 6, 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jul 6, 2021
Transactions value $
$0
Form type
4
Date filed
7/8/2021, 06:18 PM
Previous filing
Jun 30, 2021
Next filing
Jan 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Conversion of derivative security +26.2K 26.2K Jul 6, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Series A-1 Preferred Stock Conversion of derivative security -15.7K -50% 15.7K Jul 6, 2021 Common Stock 15.7K Direct F1
transaction ABOS Series B Preferred Stock Conversion of derivative security -10.5K -50% 10.5K Jul 6, 2021 Common Stock 10.5K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.